Itepekimab's inconsistent phase 3 results represent a setback for Regeneron Pharmaceuticals and Sanofi. The results do not support regulatory submissions and a 3-4 year approval delay, and lower peak sales potential looks like a best-case scenario for itepekimab. Regeneron faces a greater impact, as it is losing an important growth driver in the second half of the decade.

SANTA MONICA, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Super League Enterprise, Inc. (NASDAQ: SLE) (the “Company”), a leader in redefining how brands connect with consumers through the power of playable media, today announced that it has entered into definitive agreements in a registered direct offering with an institutional investor for the purchase and sale of approximately $670,000 of shares of Common Stock and Pre-funded Warrants.

Rivian Automotive is working with JPMorgan Chase on a potential high-yield bond sale, in part to refinance its upcoming debt, Bloomberg News reported on Friday, citing people familiar with the transaction.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming June 3, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) securities between August 8, 2024, to February 26, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON VIATRIS INC. (VTRS), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAUD.

CNBC's Deirdre Bosa joins 'Money Movers' to discuss Meta's Mark Zuckerberg and Palmer Luckey's reconciliation and the military connection that drove the reconnection.

Subscribers to Schaeffer's Weekend Trader options recommendation service received this BWXT commentary on Sunday night, along with a detailed options trade recommendation -- including complete entry and exit parameters.

A.I. isn't just changing how people use search, but it's also changing how some litigators see Alphabet's (GOOGL) antitrust case. If the Big Tech giant is found to have a search monopoly, it will be forced to divest its Google Chrome browser.

SAN FRANCISCO--(BUSINESS WIRE)--Blend Labs Inc. (NYSE: BLND), a leading digital origination platform for banks, credit unions, and mortgage lenders, today announced that its management will participate at the following investor conference: William Blair 45th Annual Growth Stock Conference Chicago, IL Wednesday, June 4, 2025 Fireside Chat at 8:00 a.m. CT The conference fireside chat will be available via live audio webcast accessible on the Investors section of the Company's website at investor.

NEW YORK CITY, NY / ACCESS Newswire / May 30, 2025 / WHY: New York, N.Y., May 30, 2025.

NEW YORK, NY / ACCESS Newswire / May 30, 2025 / If you suffered a loss on your Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/iovance-biotherapeutics-inc-lawsuit-submission-form?prid=151035&wire=1&utm_campaign=12 or contact Joseph E. Levi, Esq.

Shares of Trump Media & Technology Group Corp. DJT are trading higher Friday after company closed a $2.44 billion private placement with institutional investors.

BioLineRx Ltd's BLRX poster, which includes new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination trial, will be presented at the 2025 American Society of Clinical Oncology Annual Meeting.

GAP posts Q1 fiscal 2025 gains on strong brand performance and cost management efforts.

Warner Bros. Discovery's 5% YTD decline contrasts with streaming momentum.

Nvidia Corporation's Q1 FY2026 results crushed expectations despite a $4.5B China hit, proving the company's resilience and global demand strength. Management remains confident, highlighting robust growth in Europe, Japan, and the Middle East, and sees potential policy relief ahead. Q2 guidance projects 60%+ YoY growth even with an $8B China revenue loss, showcasing Nvidia's operational efficiency and adaptability.

RGA gets a buy rating for my initial coverage, as a top 10 firm in the reinsurance sector, a necessary segment for insurance risk transfer. A strategic deal with Equitable Holdings could drive future top-line growth, while the firm is also globally diversified in many regions. The firm has been a proven dividend grower, and has a large portfolio of income-producing fixed income assets to supplement revenue.

Argan is capitalizing on electrification and energy transition trends, with a record $1.4B order book and strong financial results fueling recent share price gains. The company stands out with no debt, robust cash reserves, healthy margins, and a proven ability to deliver large-scale energy projects across gas, solar, and bioenergy. Despite a premium valuation (35x FY2025 earnings), Argan's growth prospects, strong balance sheet, and shareholder returns justify a buy rating for long-term investors.

GSL's asset-light model, strong backlog, and robust Q1 results support our strong buy rating and target price increase to $33.30 per share. The company boasts a 93% contract coverage for 2024, 75% for 2026, and an 8.5% dividend yield, offering downside protection and earnings visibility. GSL's deleveraging, rising cash position, and disciplined fleet management enhance its financial strength, supporting ongoing free cash flow growth.

Global Payments plans to divest Payroll business to Acrisure for $1.1 billion, sharpening focus on core operations and boosting shareholder returns with post-sale proceeds.

Stantec (STN) could produce exceptional returns because of its solid growth attributes.